EHR Analysis of 67 Systems Flags Elevated Hair Loss Risk with GLP-1 Agonists

GLP-1 receptor agonists approved for diabetes, obesity, and kidney disease now show expanded signals in substance-use and neurodegenerative trials. Usage reached 11% of US adults for weight loss per Gallup polling, with lawsuits alleging non-arteritic anterior ischemic optic neuropathy filed against Novo Nordisk and Eli Lilly. Both firms reject causation. Pediatric prescriptions remain rare yet accelerated sharply; WHO 2026 guidelines explicitly withhold pharmacologic recommendations for patients under 10 citing absent long-term growth and mental-health data.

Vidal et al. analysis of multi-system EHRs quantified alopecia odds elevation while smaller Austrian cohorts reported nail disorders in 66% of users versus comparable background rates. Research on optic-nerve events remains mixed, with incidence too low for current pharmacovigilance thresholds yet prompting active litigation. Data volume from scaled prescribing now exceeds pre-approval cohorts, exposing signals invisible in registration trials.

AI-driven pharmacovigilance platforms parsing de-identified claims and EHR streams accelerate detection but raise consent and re-identification risks when pediatric records enter training sets. Operational impact includes revised labeling, restricted pediatric formularies, and mandatory post-marketing registries. Manufacturers must submit annual safety updates incorporating real-world evidence by 2028 under updated FDA guidance.

Next reporting cycle will test whether hair-loss and vision signals stabilize or intensify as cumulative exposure surpasses five years in large cohorts.